Platelet-Activating Factor (PAF) in experimental and clinical sepsis

Guenther Mathiak, Damian Szewczyk, Fizan Abdullah, Philip Ovadia, Reuven Rabinovici*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

55 Scopus citations


Despite considerable progress in understanding the pathogenic mechanisms of Gram-negative sepsis, the outcome of septic patients has not significantly improved. There are ample data that support a role for inflammatory mediators in sepsis that act in synergy with infectious agents to initiate and propagate the disease process. One such mediator is the glycerophospholipid platelet-activating factor (PAF). The objective of the present review is to summarize experimental and clinical evidence implicating PAF as a mediator in the pathomechanism of sepsis. This review is timely because many potent and selective PAF antagonists have matured for clinical development and a careful analysis of the data that support or refute the merit of clinical trials with such compounds may be important for both academic and pharmaceutical applications.

Original languageEnglish (US)
Pages (from-to)391-404
Number of pages14
Issue number6
StatePublished - Jun 1997

ASJC Scopus subject areas

  • Emergency Medicine
  • Critical Care and Intensive Care Medicine


Dive into the research topics of 'Platelet-Activating Factor (PAF) in experimental and clinical sepsis'. Together they form a unique fingerprint.

Cite this